Global Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.3 OVERVIEW OF GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET 30
1.4 LIMITATIONS 32
1.5 MARKETS COVERED 32
2 MARKET SEGMENTATION 34
2.1 MARKETS COVERED 34
2.2 GEOGRAPHICAL SCOPE 35
2.3 YEARS CONSIDERED FOR THE STUDY 36
2.4 CURRENCY AND PRICING 36
2.5 DBMR TRIPOD DATA VALIDATION MODEL 37
2.6 MULTIVARIATE MODELLING 40
2.7 TYPE LIFELINE CURVE 41
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42
2.9 DBMR MARKET POSITION GRID 43
2.10 MARKET APPLICATION COVERAGE GRID 44
2.11 VENDOR SHARE ANALYSIS 45
2.12 SECONDARY SOURCES 46
2.13 ASSUMPTIONS 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 50
5 REGULATIONS: GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET 53
5.1 UNITED STATES 53
5.1.1 ROLE OF FDA 53
5.1.2 ROLE OF CDC AND HCFA 53
5.2 EUROPEAN UNION 54
5.3 FRANCE 54
5.4 AUSTRALIA 54
5.5 SOUTH KOREA 54
6 MARKET OVERVIEW 55
6.1 DRIVERS 57
6.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER 57
6.1.2 INITIATIVES TAKEN BY MANUFACTURERS 57
6.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE 58
6.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION 58
6.1.5 GROWING MEDICAL TOURISM 59
6.2 RESTRAINTS 59
6.2.1 LACK OF STRONG CLINICAL EVIDENCE 59
6.2.2 HIGH COST 60
6.2.3 LACK OF REIMBURSEMENT 60
6.3 OPPORTUNITIES 61
6.3.1 TECHNOLOGICAL ADVANCEMENTS 61
6.3.2 EMERGENCE OF NEW PLAYERS 61
6.3.3 UNTAPPED MARKET 61
6.4 CHALLENGES 62
6.4.1 STRINGENT GOVERNMENT REGULATION 62
6.4.2 SHORTAGE OF SKILLED PERSONNEL 63
7 COVID-19 IMPACT ON GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET 64
7.1 IMPACT ON PRICE 64
7.2 IMPACT ON DEMAND 64
7.3 IMPACT ON SUPPLY 64
7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19 65
7.5 CONCLUSION: 65
8 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE 66
8.1 OVERVIEW 67
8.2 WHOLE GENOME SEQUENCING 70
8.3 ARRAY-BASED TESTS 70
9 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES 72
9.1 OVERVIEW 73
9.2 CYP2C19 76
9.3 CYP2C9 AND VKORC1 77
9.4 CYP2D6 77
9.5 HLA-B 78
9.6 HTR2A/C 78
9.7 HLA-A 79
9.8 CYP3A4 80
9.9 SLC6A4 80
9.10 MTHFR 81
9.11 COMT 82
9.12 OTHERS 82
10 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE 84
10.1 OVERVIEW 85
10.2 PRESCRIPTION DRUGS 88
10.3 OVER-THE-COUNTER MEDICATIONS 88
10.4 RECREATIONAL DRUGS 89
10.5 VITAMINS/NUTRACEUTICALS 90
11 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE 91
11.1 OVERVIEW 92
11.2 SALIVA 95
11.3 BLOOD 95
12 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION 97
12.1 OVERVIEW 98
12.2 DRUG DEVELOPMENT 101
12.3 CLINICAL PRACTICE 101
13 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER 103
13.1 OVERVIEW 104
13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 107
13.3 HEALTHCARE PROVIDERS 107
13.4 RESEARCH CENTERS AND ACADEMIC INSTITUES 108
13.5 OTHERS 109
14 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL 110
14.1 OVERVIEW 111
14.2 RETAIL PHARMACIES 114
14.3 HOSPITAL PHARMACIES 114
14.4 MAIL-ORDER PHARMACIES 115
14.5 DIRECT-TO-CUSTOMER SERVICES 116
15 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GEOGRAPHY 117
15.1 OVERVIEW 118
15.2 NORTH AMERICA 124
15.2.1 U.S. 131
15.2.2 CANADA 133
15.2.3 MEXICO 135
15.3 EUROPE 137
15.3.1 U.K. 144
15.3.2 GERMANY 146
15.3.3 FRANCE 148
15.3.4 ITALY 150
15.3.5 SPAIN 152
15.3.6 NETHERLANDS 154
15.3.7 BELGIUM 156
15.3.8 RUSSIA 158
15.3.9 SWITZERLAND 160
15.3.10 TURKEY 162
15.3.11 REST OF EUROPE 164
15.4 ASIA-PACIFIC 165
15.4.1 JAPAN 172
15.4.2 CHINA 175
15.4.3 SOUTH KOREA 178
15.4.4 INDIA 181
15.4.5 AUSTRALIA 184
15.4.6 SINGAPORE 187
15.4.7 THAILAND 190
15.4.8 MALAYSIA 193
15.4.9 INDONESIA 196
15.4.10 PHILIPPINES 199
15.4.11 REST OF ASIA-PACIFIC 202
15.5 SOUTH AMERICA 202
15.5.1 BRAZIL 210
15.5.2 ARGENTINA 212
15.5.3 REST OF SOUTH AMERICA 214
15.6 MIDDLE EAST & AFRICA 215
15.6.1 SOUTH AFRICA 222
15.6.2 SAUDI ARABIA 224
15.6.3 UAE 226
15.6.4 ISRAEL 228
15.6.5 EGYPT 230
15.6.6 REST OF MIDDLE EAST & AFRICA 232
16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE 233
16.1 COMPANY SHARE ANALYSIS: GLOBAL 233
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 234
16.3 COMPANY SHARE ANALYSIS: EUROPE 235
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 236
17 SWOT ANALYSIS 237
18 COMPANY PROFILE 238
18.1 MYRIAD GENETICS, INC. 238
18.1.1 COMPANY SNAPSHOT 238
18.1.2 REVENUE ANALYSIS 239
18.1.3 COMPANY SHARE ANALYSIS 239
18.1.4 PRODUCT PORTFOLIO 239
18.1.5 RECENT DEVELOPMENTS 240
18.2 THERMO FISHER SCIENTIFIC INC. 242
18.2.1 COMPANY SNAPSHOT 242
18.2.2 REVENUE ANALYSIS 243
18.2.3 COMPANY SHARE ANALYSIS 243
18.2.4 PRODUCT PORTFOLIO 243
18.2.5 RECENT DEVELOPMENT 244
18.3 STADA ARZNEIMITTEL AG 245
18.3.1 COMPANY SNAPSHOT 245
18.3.2 REVENUE ANALYSIS 246
18.3.3 COMPANY SHARE ANALYSIS 246
18.3.4 PRODUCT PORTFOLIO 246
18.3.5 RECENT DEVELOPMENTS 247
18.4 SONIC HEALTHCARE 248
18.4.1 COMPANY SNAPSHOT 248
18.4.2 REVENUE ANALYSIS 248
18.4.3 COMPANY SHARE ANALYSIS 249
18.4.4 PRODUCT PORTFOLIO 249
18.4.5 RECENT DEVELOPMENT 249
18.5 ILLUMINA, INC. 250
18.5.1 COMPANY SNAPSHOT 250
18.5.2 REVENUE ANALYSIS 250
18.5.3 COMPANY SHARE ANALYSIS 251
18.5.4 PRODUCT PORTFOLIO 251
18.5.5 RECENT DEVELOPMENTS 251
18.6 AB-BIOTICS, S.A. 253
18.6.1 COMPANY SNAPSHOT 253
18.6.2 REVENUE ANALYSIS 253
18.6.3 6.3 PRODUCT PORTFOLIO 254
18.6.4 RECENT DEVELOPMENTS 254
18.7 ALTHEADX 256
18.7.1 COMPANY SNAPSHOT 256
18.7.2 PRODUCT PORTFOLIO 256
18.7.3 RECENT DEVELOPMENT 257
18.8 BIOGENIQ INC. 258
18.8.1 COMPANY SNAPSHOT 258
18.8.2 PRODUCT PORTFOLIO 259
18.8.3 RECENT DEVELOPMENT 259
18.9 COLOR 260
18.9.1 COMPANY SNAPSHOT 260
18.9.2 PRODUCT PORTFOLIO 260
18.9.3 RECENT DEVELOPMENTS 260
18.10 CNSDOSE 262
18.10.1 COMPANY SNAPSHOT 262
18.10.2 PRODUCT PORTFOLIO 262
18.10.3 RECENT DEVELOPMENT 262
18.11 CORIELL LIFE SCIENCES 263
18.11.1 COMPANY SNAPSHOT 263
18.11.2 PRODUCT PORTFOLIO 263
18.11.3 RECENT DEVELOPMENTS 263
18.12 DYNAMIC DNA LABORATORIES 265
18.12.1 COMPANY SNAPSHOT 265
18.12.2 PRODUCT PORTFOLIO 265
18.12.3 RECENT DEVELOPMENTS 265
18.13 GENELEX 267
18.13.1 COMPANY SNAPSHOT 267
18.13.2 PRODUCT PORTFOLIO 267
18.13.3 RECENT DEVELOPMENT 267
18.14 GENOMIND, INC. 268
18.14.1 COMPANY SNAPSHOT 268
18.14.2 PRODUCT PORTFOLIO 268
18.14.3 RECENT DEVELOPMENTS 268
18.15 GENXYS 270
18.15.1 COMPANY SNAPSHOT 270
18.15.2 PRODUCT PORTFOLIO 270
18.15.3 RECENT DEVELOPMENTS 271
18.16 HEALTHSPEK 272
18.16.1 COMPANY SNAPSHOT 272
18.16.2 PRODUCT PORTFOLIO 272
18.16.3 RECENT DEVELOPMENT 272
18.17 HUDSONALPHA HEALTH ALLIANCE (A DIVISION OF HUDSONALPHA) 273
18.17.1 COMPANY SNAPSHOT 273
18.17.2 PRODUCT PORTFOLIO 273
18.17.3 RECENT DEVELOPMENT 273
18.18 LUMINEX CORPORATION 274
18.18.1 COMPANY SNAPSHOT 274
18.18.2 REVENUE ANALYSIS 274
18.18.3 PRODUCT PORTFOLIO 275
18.18.4 RECENT DEVELOPMENTS 275
18.19 MILLENNIUM HEALTH 276
18.19.1 COMPANY SNAPSHOT 276
18.19.2 PRODUCT PORTFOLIO 276
18.19.3 RECENT DEVELOPMENTS 276
18.20 MYDNA LIFE AUSTRALIA PTY LTD. 278
18.20.1 COMPANY SNAPSHOT 278
18.20.2 PRODUCT PORTFOLIO 278
18.20.3 RECENT DEVELOPMENT 278
18.21 ONEOME 279
18.21.1 COMPANY SNAPSHOT 279
18.21.2 PRODUCT PORTFOLIO 279
18.21.3 RECENT DEVELOPMENTS 279
18.22 OMECARE 280
18.22.1 COMPANY SNAPSHOT 280
18.22.2 PRODUCT PORTFOLIO 280
18.22.3 RECENT DEVELOPMENT 280
18.23 PERKINELMER INC. 282
18.23.1 COMPANY SNAPSHOT 282
18.23.2 REVENUE ANALYSIS 282
18.23.3 PRODUCT PORTFOLIO 283
18.23.4 RECENT DEVELOPMENTS 284
18.24 R-BIOPHARM AG 285
18.24.1 COMPANY SNAPSHOT 285
18.24.2 PRODUCT PORTFOLIO 285
18.24.3 RECENT DEVELOPMENTS 285
19 QUESTIONNAIRE 287
20 RELATED REPORTS 292